Product Data Sheet

Product Name: Mepazine
Cat. No.: GC68218

Chemical Properties

Cas. No.	60-89-9		
Formula	$C_{19}H_{22}N_2S$	M.Wt	310.46
Solubility	DMSO : 130 mg/mL (418.73 mM; Need ultrasonic)	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	Mepazine		

Background

Mepazine (Pecazine) is a potent and selective **MALT1** protease inhibitor with **IC_{50}**s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine affects viability of ABC-DLBCL cells by enhancing **Apoptosis**[1].

Mepazine (5-20 μM; 4 days) causes a decrease of cell viability in the activated B cell subtype of diffuse large B cell lymphoma (ABCDLBCL) cells, without significantly affecting GCB-DLBCL cells[1].

Cell Viability Assay[1]

Cell Line:	ABC-DLBCL cell lines (HBL1, OCI-Ly3, U2932, TMD8, OCI-Ly10) and GCB-DLBCL cell lines (BJAB, Su-DHL-6, Su-DHL-4)
Concentration:	5, 10, and 20 μM
Incubation Time:	4 days

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Result:	Caused a decrease of cell viability in the ABC-DLBCL cells HBL1, OCI-Ly3, U2932, and TMD8, without significantly affecting GCB-DLBCL cells.

Mepazine (16 mg/kg; intraperitoneal administration) interferes with growth and induces apoptosis of ABC-DLBCL cell line OCI-Ly10 in NOD/scid IL-2Rg^{null} (NSG) mice with a murine DLBCL xenogeneic tumor model. Daily administration of Mepazine strongly impairs the expansion of the ABC-DLBCL cell line OCI-Ly10[1].

Animal Model:	6- to 8-week-old female NOD.Cg-*Prkdc*^{scid} *Il2rg*^{tm1Wjl}/SzJ (NSG) mice with a murine DLBCL xenogeneic tumor model[1]
Dosage:	400 μg per animal (25 g), corresponding to approximately 16 mg/kg.
Administration:	Intraperitoneal administration; started 1 or 12 days after transplantation and given continuously every 24 hr; daily application
Result:	Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10.

[1]. Nagel D, et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell. 2012 Dec 11;22(6):825-37.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA